Info

CoGenesys is a biopharmaceutical company focused on developing innovative long-acting medicines across broad therapeutic areas. Our goal, as an early-stage drug development organization, is to execute a business plan unique within the pharmaceutical industry: to rapidly and efficiently generate medically important, stable, long-acting bio-therapeutics, which are then available for sale, license or further partner-funded development following early-stage demonstration of safety and proof of concept in man. At CoGenesys, we are applying a proprietary and clinically validated technology that allows the improvement and expanded use of many known and clinically established therapeutic peptides and proteins as well as the creation of new medicines from known pharmaceutically relevant peptides. Without the benefit of our technology, these peptides and proteins have numerous shortcomings including poor bio-availability, the need for frequent dosing, and unwanted side-effect profiles. CoGenesys' highly experienced management and development teams have a significant track record in translating early drug opportunities into clinically-proven candidates for the pharmaceutical market. Our state of the art research and manufacturing facility is fully equipped, supporting both GLP development and cGMP manufacture of biologics. We have capitalized on the depth of our pipeline and the breadth of our technology to develop drug candidates that will address a broad spectrum of unmet needs including diabetes, cardiovascular disease, and enzyme replacement therapy, among others. We currently have several well-advanced product development programs including our lead clinical candidate Cardeva, a long-acting natriuretic peptide being developed for outpatient treatment of chronic heart failure. The second program, Neugranin, a long-acting form of granulocyte colony stimulating factor (GCSF), is being readied for clinical development as an agent initially for the treatment of febrile neutropenia associated with chemotherapy.